Factor nuclear kB (NF-kB): Signalosoma y su importancia en enfermedades infalamatorias y cáncer
Nuclear factor kB (NF-KB): signalosoma and its importance in cancer and inflammatories diseases
Palabras clave:
ataxia telangiectasia, cáncer (neoplasia), inflamación, enzimas, antioxidantes. (es)ataxia telangiectasia, neoplasms, inflammation, enzymes, antioxidants. (en)
Nowadays, the NF-κB activation by oxidative stress, genotoxic stress and DNA damage pathways. In contrast with the classical pathway, in this pathway there are a SUMOilation and nuclear translocation of NEMO. In nucleus NEMO interact with ataxia telangiectasia muted which is activated by chromatin changes and DNA damage. The complex ATM/NEMO is later translocated to cytoplasm where IKKβ is phosphorilated by ATM bringing to ubiquitination and thus NF-κB releasing which is translocated to nucleus. NF-κB induces survival rising antioxidants enzymes as superoxide dismutase, catalase and glutathione. These enzymes act in the control of oxidative species levels in the cell. NF-κB over expression is related with inflammation and cancer. Nowadays, is development a pharmacological search which can act inhibiting NF-κB signalosome molecules, not only to inflammatory disease whereas to radiotherapy and chemotherapy cancer resistance.
Referencias
Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell. 1986;47:921-928.
Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195-2224.
. Gloire G , Legrand-Poels S , Piette J . NF-κB activation by reactive oxygen species : Fifteen years later . Biochem Pharmacol . 2006 ; 72 : 1493-1505 .
Beinke S, Ley S. Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J. 2004;382:393-409.
Fujita T, Nolan G, Liou H, Scott M, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through p50 homodimers. Genes Dev. 1993;7:1354-1363.
Farrow B, Evers B. Inflammation and the develop-ment of pancreatic cancer. Surg Oncol. 2002;10:153– 169.
Gerondakis S, Morrice N, Richardson I, Wetten-hall R, Fecondo J, Grumont R. The activity of a 70kDa IκB molecule identical to the carboxyl terminus of the p105 NF-κB precursor is modulated by protein kinase A. Cell Growth Differ. 1993;4:617-627.
Chen L, Greene W. Shaping the nuclear action of NF-κB. Nat Immunol Rev. 2004;5:392-401.
Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell. 1998;93:1231-1240.
Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 1997;91: 243-252.
Lee JI, Burckart GJ. Nuclear factor kB: Important transcription factor and therapeutic target. J Clin Pharmacol. 1998;38:981-993.
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000;18:621-663.
May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-ka-ppaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science. 2000;289:1550-1554.
Verma UN, Yamamoto Y, Prajapati S, Gaynor RB. Nuclear role of I kappa B kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa B-dependent gene expression. J Biol Chem. 2004;279:3509-3515.
Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280-288.
Martin A, Fresno M. Tumor necrosis factoralpha activation of NF-κB requires the phosphorylation of Ser-471 in the transactivation domain of c-Rel. J Biol Chem. 2000;275:24383–24391.
O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol. 2006;18:3-9.
Weil R, Israel A. T-cell-receptor- and B-cell-receptor-mediated activation of NF-kappaB in lymphocytes. Curr Opin Immunol. 2004;16:374-381.
Pomerantz J, Baltimore D. Two pathways to NF-κB. Mol Cell. 2002;10:693-701.
Takaesu G, Surabhi R, Park K, Ninomiya-Tsuji J, Matsumoto K, Gaynor R. TAK1 is critical for IκB kinase-mediated activation of the NF-κB pathway. J Mol Biol. 2003;326:105-115.
Liu Y. Ubiquitin ligases and the immune response. Annu Rev Immunol. 2004; 22:81-127.
Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. 2002;3:958-965.
Kato T, Delhase M, Hoffmann A, Karin M. CKII is a C-terminal IκB kinase responsible for NF-κB activation during UV response. Mol Cell. 2003;12:829-839.
Conner E, Grisham M. Inflammation, free radicals, and antioxidants. Nutrition. 1996;12:274-277.
Huang T, Wuerzberger-Davis S, Wu Z, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell. 2003;115:565-576.
Habraken Y, Piette J and Piret B. S phase dependence and involvement of NF-kappaB activating kinase to NF-kappaB activation by camptothecin. Biochem Pharmacol. 2001;62:603-616.
Guo G, Yan-Sanders Y, Lyn-Cook B, Wang T, Ta-mae D, Oqi J, et al. Manganese Superoxide Dismu-tase-Mediated Gene Expression in Radiation-Induced Adaptive Responses. Mol Cell Biol. 2003;23:2362-2378.
Zhou L, Johnson A, Rando T. NF-κB and AP-1 mediate transcriptional responses to oxidative stress in skele-tal muscle cells. Free Radic Biol Med. 2001; 31:1405-1416.
Morales A, Miranda M, Sanchez-Reyes A, Colell A, Biete A, Fernández-Checa J. Transcriptional regulation of the heavy subunit chain of g-glutamylcysteine synthetase by ionizing radiation. FEBS Letters. 1998; 427:15-20.
Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
Grossmann M, Nakamura Y, Grumont R, Gerondakis S. New insights into the roles of ReL/NF-κB transcription factors in immune function, hemopoiesis and human disease. Int J Biochem Cell Biol. 1999;31:1209-1219.
Meager A. Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev. 1999;10:27-39.
Opipari AW Jr, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem. 1992;267:12424-12427.
Wissing D, Mouritzen H, Jaattela M. TNF-induced mitochondrial changes and activation of apoptotic proteases are inhibited by A20. Free Radic Biol Med. 1998;25:57-65.
Zhang SQ, Kovalenko A, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity. 2000; 2: 301-311.
Ferran C, Stroka DM, Badrichani AZ, Cooper JT, Wrighton CJ, Soares M, Grey ST, Bach FH. A20 inhibits NF-κB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apopto-sis. Blood. 1998;91:2249-2258.
Beyaert R, Heyninck K, Van Huffel S. A20 and A20-Binding proteins as cellular inhibitors of nuclear factor-κB-dependent gene expression and apoptosis. Biochem Pharmacol. 2000;60:1143-1151.
Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, Fiers W, et al. The zinc finger protein A20 inhibits TNF-induced NF-κB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB inhibiting protein ABIN. J Cell Biol. 1999;145:1471-1482.
Chen F, Bhatia D, Chang Q and Castranova V. Finding NEMO by K63-linked polyubiquitin chain. Cell Death Differ. 2006;13:1835-1838.
Sun X, Zhang H.NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 2007;22:1387-1398.
Dejardin E. The alternative NF-κB pathway from biochemistry to biology: Pitfalls and promises for future drug development. Biochem Pharmacol. 2006;72:1161-1179.
Veiby OP, Read MA. Chemoresistance: Impact of nuclear factor (NF)-κB inhibition by small interfering RNA. Clin Cancer Res. 2004;10:3333-3341.
Chan A, Giovannucci E, Schernhammer E, Coldi-tz G, Hunter D, Willett W, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004;140:157-166.
Olivier S, Robe P, Bours V. Can NF-κB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol. 2006;72:1054-1068.
Kopp E, Ghosh S. Inhibition of NF-kappa B by so-dium salicylate and aspirin. Science. 1994;265:956-959.
Yin M, Yamamoto Y, Gaynor R. The anti-inflamma-tory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77-80.
Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004;23:9247-9258.
Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulin-dac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999;274:27307-27314.
Stark L, Dunlop M. Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis. Mol Cell Biol. 2005;25:5985–6004.
Ito K, Barnes P, Adcock I. Glucocorticoid receptor recruitment of HDAC 2 inhibits interleukin-1-β-induced histone H4 acetilation on lysines 8 and 12. Mol Cell Biol. 2000;20:6891-6903.
Chang E, Zheng T, Weir E, Borowitz M, Mann R, Spiegelman D, et al. Aspirin and the risk of Hodgkin's lymphoma in a population-based case–control study. J Natl Cancer Inst. 2004;96:305-315.
De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003;24:488-522.
Scheinman RI, Cogswell PC, Lofquist AK, Bald-win Jr AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
Kagoshima M, Wilcke T, Ito K, Tsaprouni L, Bar-nes PJ, Punchard N, et al. Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation. Eur J Pharmacol. 2001;429:327-334.
Ray DM, Akbiyik F, Bernstein SH and Phipps RP. CD40 engagement prevents peroxisome proliferatoractivated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaBdependent mechanism. J Immunol. 2005;174:4060-4069.
Keifer JA, Guttridge DC, Ashburner BP, Baldwin Jr AS. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276:22382-22387.
Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther. 2008;33:219-226.
Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007; 39:1489-1499.
Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314–322.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-4530.
Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000;18:109-121.
Adams J, Palombella VJ, Sausville EA, Johnson J, Descree A, Lazarus DD et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
Richardson P, Mitsiades C, Hideshima T. and Anderson C. Bortezomib: proteasome inhibition as an effective anticancer therapy, Annu Rev Med. 2006;57:33-47.
Nakajima H, Fujiwara H, Furuichi Y, Tanaka Kei-ji, Shimbara N. A novel small-molecule inhibitor of NF-κB signaling. Biochem Biophys Res Comun. 2008; 368:1007-1013.
Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairos MJ, et al. Brothers in arms: DNA enzymes, short interfering RNA and the emerging wave of small-molecule nucleic acid-based gene-silencing stra-tegies. Am J Pathol. 2007;171:1079-1088.
Morishita R, Tomita N, Kaneda Y, Ogihara T. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol. 2004;4:139-146.
Guo J, Verma U, Gaynor R, Frenkel E, Becerra C. Enhanced chemosensitivity to irinotecan by RNA interference. Mediated down-regulation of the nuclear factor-κB p65 subunit. Clinical Cancer Res. 2004;10:3333-3341.
Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, et al. Intratumoral injection of oligonucleotides to the NFkB binding site inhibits cachexia in a mouse tumor model. Gene Ther. 1999;6:91-97.
Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, Tomita N, et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther. 2001;8:905-912.
Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 1999;42:2532-2542.
Tomita T, Takano H, Tomita N, Morishita R, Ka-neko M, Shi K, et al. Transcription factor decoy for nuclear factor kappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology. 2000;39:749-757.
Pham C, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, et al. Ferritin heavy chain upregulation by NF-κB inhibits TNF-α-induced apoptosis by suppressing reactive oxygen species. Cell. 2004;119:529-542.
Haddad J. Oxygen sensing and oxidant/redox-related pathways. Biochem Biophys Res Commun. 2004;316:969-977.
Xu Y, Porntadavity S and Clair D. Transcriptional regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2). Biochem J. 2002;362:401-412.
Visitas a la página del resumen del artículo
Descargas
Cómo citar
Licencia
Derechos de autor 2008 Revista de la Facultad de Medicina

Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-








